Which ante mortem clinical features predict progressive supranuclear palsy pathology?

Further Publications NeurologyFurther Publications Psychiatry

Association of MAPT Subhaplotypes With Risk of Progressive Supranuclear Palsy and Severity of Tau Pathology

JAMA Neurol.

Heckman MG, Brennan RR, Labbé C, Soto AI, Koga S, DeTure MA, Murray ME, Petersen RC, Boeve BF, van Gerpen JA, Uitti RJ, Wszolek ZK, Rademakers R, Dickson DW, Ross OA

doi: 10.1001/jamaneurol.

Parkinson’s Disease

Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches

Lancet Neurol.

Boxer AL, Yu JT, Golbe LI, Litvan I, Lang AE, Höglinger GU

doi: 10.1016/

Aging and Cognitive Functions

Predictors of survival in progressive supranuclear palsy and multiple system atrophy: a systematic review and meta-analysis

J Neurol Neurosurg Psychiatry.

Glasmacher SA, Leigh PN, Saha RA

doi: 10.1136/jnnp-2016-314956.

Multiple Sclerosis

Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis

Brain.

Elliott C, Belachew S, Wolinsky JS, Hauser SL, Kappos L, Barkhof F, Bernasconi C, Fecker J, Model F, Wei W, Arnold DL

doi: 10.1093/brain/awz212.

Further Publications NeurologyFurther Publications Psychiatry

Disrupted structural connectivity of fronto-deep gray matter pathways in progressive supranuclear palsy

Neuroimage Clin.

Abos A, Segura B, Baggio HC, Campabadal A, Uribe C, Garrido A, Camara A, Muñoz E, Valldeoriola F, Marti MJ, Junque C, Compta Y

doi: 10.1016/j.nicl.

Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation

Lancet Neurol.

Latourelle JC, Beste MT, Hadzi TC, Miller RE, Oppenheim JN, Valko MP, Wuest DM, Church BW, Khalil IG, Hayete B, Venuto CS

doi: 10.1016/

Further Publications Neurology

Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial

Lancet Neurol

Höglinger GU, Litvan I, Mendonca N, Wang D, Zheng H, Rendenbach-Mueller B, Lon HK, Jin Z, Fisseha N, Budur K, Gold M, Ryman D, Florian H, Arise Investigators.

doi: 10.1016/S1474-4422(20)30489-0

RECOMMENDED

Further Publications NeurologyFurther Publications Psychiatry

Improving diagnostic accuracy of multiple system atrophy: a clinicopathological study

Brain.

Miki Y, Foti SC, Asi YT, Tsushima E, Quinn N, Ling H, Holton JL

doi: 10.1093/brain/awz189.

Alzheimer’s Disease

Mechanisms of Cell-to-Cell Transmission of Pathological Tau: A Review

JAMA Neurol.

Gibbons GS, Lee VMY, Trojanowski JQ

doi: 10.1001/

Related content

Association of MAPT Subhaplotypes With Risk of Progressive Supranuclear Palsy and Severity of Tau Pathology

Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches

Predictors of survival in progressive supranuclear palsy and multiple system atrophy: a systematic review and meta-analysis

Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis

Disrupted structural connectivity of fronto-deep gray matter pathways in progressive supranuclear palsy

Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation

Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial

Improving diagnostic accuracy of multiple system atrophy: a clinicopathological study

Mechanisms of Cell-to-Cell Transmission of Pathological Tau: A Review